ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD 10.82
+1.03 (10.52%)
Jul 17, 2025, 4:08 PM HKT
HKG:1541 Revenue
In the year 2024, ImmuneOnco Biopharmaceuticals (Shanghai) had annual revenue of 79.54M CNY with 933.61% growth. ImmuneOnco Biopharmaceuticals (Shanghai) had revenue of 78.82M in the half year ending December 31, 2024, with 1,397.00% growth.
Revenue
79.54M CNY
Revenue Growth
+933.61%
P/S Ratio
47.11
Revenue / Employee
509.85K CNY
Employees
156
Market Cap
3.99B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 79.54M | 71.84M | 933.61% |
| Dec 31, 2023 | 7.70M | 2.01M | 35.24% |
| Dec 31, 2022 | 5.69M | -8.12M | -58.79% |
| Dec 31, 2021 | 13.81M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition